Arvinas, Inc.
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
(0.0% 1d) (-20.6% 1m) (19.9% 1y) (0.0% 2d) (-4.3% 3d) (-6.3% 7d) (-10.04% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 2,220,706,247
http://www.arvinas.com
Sec Filling | Patents | 133 employees
(US) Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
add to watch list Paper trade email alert is off
Press-releases
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
| Email alert
Add to watchlist
business
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.18%
H: 0.4%
C: -0.14%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: -3.22%
H: 4.58%
C: 3.23%
medical
Arvinas to Participate in Upcoming Investor Conferences
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: -3.29%
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.22%
H: 0.29%
C: -0.85%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -1.6%
year update financial results
Arvinas Announces Chief Financial Officer Transition
Published: 2024-02-20 (Crawled : 21:00) - globenewswire.com
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: -3.58%
H: 2.58%
C: -2.23%
financial
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: -1.55%
H: 0.95%
C: -1.75%
arv-102 protac disease protein neurodegenerative
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: 0.37%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: -1.09%
H: 5.61%
C: 4.49%
first breast cancer trial therapeutics advanced
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.34%
H: 3.99%
C: 3.15%
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: 0.91%
H: 5.05%
C: 4.9%
arv-471 fda breast cancer treatment designation
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
Published: 2024-02-01 (Crawled : 22:00) - globenewswire.com
ARVN | $32.51 -4.38% -4.58% 470K
|
Health Technology
|
| O: -1.12%
H: 3.3%
C: 1.84%
conference
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10